You are here: Industry Insights > Osimertinib

News List

What Sparks Will Come from the Collaboration Between CSPC and AstraZeneca? wan
October 18, 2024
On October 7, 2024, CSPC Pharmaceutical Group Co., Ltd entered into a significant collaboration agreement with AstraZeneca, creating quite a stir in the pharmaceutical industry.
NICE recommends osimertinib for non-small cell lung cancer (NSCLC) EuropeanPharmaceuticalReview
December 02, 2021
The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending osimertinib within the Cancer Drugs Fund (CDF).
AstraZeneca Pharma India files writ petition in Delhi High Court against NPPA demand notice expresspharma
July 01, 2021
The notice of demand alleges that the company has overcharged about Rs 157.38 crore from March 8, 2019 to January 31, 2021, for Tagrisso (Osimertinib) 80 mg tablets.
Zydus Cadila gets tentative US FDA nod for Osimertinib Tablets expresspharma
June 04, 2021
Zydus Cadila has received tentative approval from the USFDA to market Osimertinib Tablets in the strengths of 40 mg and 80 mg (US RLD: Tagrisso Tablets). Osimertinib is used to treat lung cancer.
AstraZeneca Pharma India gets DCGI approval for Osimertinib tablets expresspharma
March 11, 2021
AstraZeneca Pharma India has received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India for Osimertinib 40mg/80mg film-coated tablets (Tagrisso).
First-Line Osimertinib May Up Survival in EGFR-Mutated NSCLC drugs
December 26, 2019
For patients with previously untreated advanced non-small cell lung cancer (NSCLC) with an EGFR mutation, overall survival is longer for treatment with osimertinib rather than ...
China grants Tagrisso (osimertinib) marketing authorisation europeanpharmaceuticalreview
September 06, 2019
Following positive clinical trials, the Tagrisso drug has been given marketing authorisation in China for treatment of NSCLC.
Decision by NICE for the use of osimertinib to be appealed europeanpharmaceuticalreview
July 08, 2019
A pharmaceutical company will appeal a decision by NICE to not recommend osimertinib for use within NHS England.
How Hot is the Third-generation EGFR-TKI? PharmaSources/Caicai
April 03, 2019
BPI-7711 is a third-generation EGFR-TKI, making Beta Pharma the fourth Chinese pharmaceutical enterprises that enter the Phase III clinical trial of the variety following ACEA, Hansoh, and Allist.
Sales of Osimertinib Approaching RMB 2 Billion in China in 2018 PharmaSources/Caicai
April 03, 2019
Global sales of osimertinib reached USD 1.86 billion in 2018, growing by 95%; it has become the best-selling tumor drug of AstraZeneca...

Previous page 1 2 Next page